# BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

> **NCT01519323** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 6 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** vemurafenib

## Key facts

- **NCT ID:** NCT01519323
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study was terminated due to low enrollment.
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519323, "BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01519323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*